BRIGHTLINE-1: When a Negative Trial Reveals Two Active Therapies.
Where this comes from
- Record sourced from PubMed, PMID 42599166.
- Also identified by DOI 10.1158/1078-0432.CCR-26-2134.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Although BRIGHTLINE-1 was headlined as a "negative trial," brigimadlin showed clear biological activity, with median PFS of 8.4 months, ORR of 22.3%, and translational evidence of p53 reactivation. Its failure largely reflects flawed control-arm assumptions, as doxorubicin outperformed retrospective expectations and established a new prospective benchmark in DDLPS.